SCHEMBL2570482

SCHEMBL2570482

COC(=O)C1=C(C)NC(=O)NC1c1cc(F)cc(F)c1

nearest known ligand 0.67

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GUSB P08236 1/20 0.61
PKM P14618 2/20 0.61
GAA P10253 3/20 0.57
TSHR P16473 2/20 0.57
LMNA P02545 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
HSD17B10 Q99714 1/20 0.57
ADORA2B P29275 1/20 0.54
MAPT P10636 1/20 0.53
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
HPGD P15428 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2569532 0.84 USP2 (0.52) GUSBPKMGAAHSD17B10MAPT
SCHEMBL19752687 0.83 GUSB (0.64) GUSBPKMGAATSHRLMNA
SCHEMBL19752623 0.83 GUSB (0.64) GUSBPKMGAATSHRLMNA
SCHEMBL19752674 0.80 USP2 (0.71) GUSBPKMTSHRHSD17B10ADORA2B
SCHEMBL10279640 0.80 PKM (0.67) GUSBPKMGAATSHRHSD17B10
SCHEMBL5327469 0.80 USP2 (0.71) GUSBPKMTSHRHSD17B10ADORA2B
SCHEMBL10113484 0.80 GAA (0.62) GUSBPKMGAATSHRLMNA
SCHEMBL10112947 0.79 HSD17B10 (0.69) GUSBPKMGAATSHRHSD17B10
SCHEMBL13753875 0.78 GAA (0.64) GUSBPKMGAATSHRLMNA
SCHEMBL28595517 0.78 ALDH1A1 (0.78) GUSBPKMGAATSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633740-B1 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-11-09 EP disclosed
EP-1633740-B1 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-11-09 EP disclosed
US-7560467-B2 Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-14 US disclosed
US-7560467-B2 Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-14 US disclosed
US-7560467-B2 Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-14 US disclosed
EP-1633740-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-11-19 EP disclosed
US-20070099944-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-05-03 US disclosed
US-20070099944-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-05-03 US disclosed
US-20070099944-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-05-03 US disclosed
EP-1633740-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2006-03-15 EP disclosed
WO-2004112719-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099944-A1 Chemical compounds ROCK1, ROCK2, CIT GUSB 4287/4885PKM 602/4885GAA 1868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.